...
首页> 外文期刊>Molecular Immunology >Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells
【24h】

Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells

机译:实时分析mAb介导的B细胞系和慢性淋巴细胞性白血病B细胞的补体依赖性细胞毒性中细胞事件的详细序列

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Complement-dependent cytotoxicity is an important mechanism of action of certain mAbs used in cancer immunotherapy, including ofatumumab and rituximab. However, the detailed sequence of cellular changes that occur in nucleated cells attacked by mAb and complement has not been delineated. Recently developed CD20 mAbs, engineered to form hexamers on binding to cells, react with B-cells in serum, chelate C1q, and then activate complement and promote cell killing considerably more effectively than their wild-type precursors. We used these engineered mAbs as a model to investigate the sequence of events that occur when mAbs bind to B-cell lines and to primary cells from patients with chronic lymphocytic leukemia and then activate complement. Based on four-color confocal microscopy real-time movies and high resolution digital imaging, we find that after CD20 mAb binding and C1q uptake, C3b deposits on cells, followed by Ca2+ influx, revealed by bright green signals generated on cells labeled with FLUO-4, a Ca2+ indicator. The bright FLUO-4/Ca2+ signal fades, replaced by punctate green signals in mitochondria, indicating Ca2+ localization. This step leads to mitochondrial poisoning followed by cell death. The entire sequence is completed in <2 min for hexamerization-enhanced CD20 mAb-mediated killing. To our knowledge this is the first time the entire process has been characterized in detail in real time. By identifying multiple discrete steps in the cytotoxic pathway for nucleated cells our findings may inform future development and more effective application of complement-fixing mAbs to cancer treatment. (C) 2015 Elsevier Ltd. All rights reserved.
机译:补体依赖性细胞毒性是用于癌症免疫治疗的某些mAb(包括ofatumumab和rituximab)的重要作用机制。然而,尚未描述在mAb和补体攻击的有核细胞中发生的细胞变化的详细顺序。最近开发的CD20 mAb,经设计可与细胞结合形成六聚体,与血清中的B细胞反应,螯合C1q,然后激活补体,并比其野生型前体更有效地促进细胞杀伤。我们使用这些工程单克隆抗体作为模型来研究单克隆抗体与B细胞系和慢性淋巴细胞性白血病患者的原代细胞结合然后激活补体时发生的事件序列。基于四色共聚焦显微镜实时电影和高分辨率数字成像,我们发现在CD20 mAb结合和C1q吸收后,C3b沉积在细胞上,然后Ca2 +大量涌入,并被标记为FLUO- 4,Ca 2+指示剂。明亮的FLUO-4 / Ca2 +信号逐渐消失,由线粒体中的点状绿色信号取代,表明Ca2 +定位。此步骤导致线粒体中毒,随后细胞死亡。整个序列在不到2分钟的时间内完成,以增强六聚化CD20 mAb介导的杀伤作用。据我们所知,这是首次对整个过程进行实时详细表征。通过确定有核细胞的细胞毒性途径中的多个离散步骤,我们的发现可能为将来的发展和更有效地应用补体结合单克隆抗体在癌症治疗中提供参考。 (C)2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号